They inferred that high grade serous ovarian cancer with mutations in BRCA1/2 may be more sensitive to immune checkpoint inhibitors PD-1 and PD-L1 in comparison with tumors proficient in HR repair [29]. The gene discussed is CD274; the disease is ovarian serous adenocarcinoma.